Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 4
2010 1
2012 4
2013 2
2014 1
2015 4
2016 2
2017 3
2018 4
2019 4
2020 6
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE, Rose MJ. Neunert CE, et al. Blood Adv. 2019 Jun 25;3(12):1907-1915. doi: 10.1182/bloodadvances.2019000279. Blood Adv. 2019. PMID: 31239245 Free PMC article. Review.
Since successful cloning of thrombopoietin (TPO) in 1994, significant advances have been made in the development of recombinant TPO receptor agonists. The US Food and Drug Administration (FDA) has approved 2 agents for use in patients with immune thrombocytopenia (ITP): el …
Since successful cloning of thrombopoietin (TPO) in 1994, significant advances have been made in the development of recombinant TPO r …
Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study.
Schifferli A, Rüfer A, Rovo A, Nimmerjahn F, Cantoni N, Holbro A, Favre G, Dirks J, Wieland A, Faeth H, Pereira R, Kühne T. Schifferli A, et al. Br J Haematol. 2023 Oct;203(1):119-130. doi: 10.1111/bjh.19074. Br J Haematol. 2023. PMID: 37735543 Free article.
In addition to immunological data, secondary end-points included the sustained remission off-treatment (SROT) rate at 1 year, romiplostim dose, platelet count and bleedings. Scheduled discontinuation of romiplostim and SROT were achieved in six patients with newly d …
In addition to immunological data, secondary end-points included the sustained remission off-treatment (SROT) rate at 1 year, romiplostim …
"ITP" is not always immune thrombocytopenia.
Holyome A, Cooper N, Qureshi A, Bain BJ. Holyome A, et al. Am J Hematol. 2020 Dec;95(12):1614-1615. doi: 10.1002/ajh.25872. Epub 2020 Jun 12. Am J Hematol. 2020. PMID: 32419170 Free article. No abstract available.
A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli.
Hashemzaei M, Ghoshoon MB, Jamshidi M, Moradbeygi F, Hashemzehi A. Hashemzaei M, et al. Recent Pat Biotechnol. 2024;18(2):95-109. doi: 10.2174/1872208317666230503094451. Recent Pat Biotechnol. 2024. PMID: 38282441 Review.
It consists of four high-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc domain. Escherichia coli is a good host for the fabrication of recombinant proteins such as romiplostim. The expression of a gene intended in E. coli is depende …
It consists of four high-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc domain. Escherichia coli is a good …
Lowering the boom on lower-risk myelodysplastic syndromes.
Sekeres MA, Patel BJ. Sekeres MA, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):367-372. doi: 10.1182/hematology.2019000040. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808873 Free PMC article. Review.
Therapy is geared toward predominating cytopenias, with erythropoiesis-stimulating agents luspatercept and lenalidomide used to ameliorate anemia, romiplostim and eltrombopag tackling thrombocytopenia, and hypomethylating agents and antithymocyte globulin palliating pancyt …
Therapy is geared toward predominating cytopenias, with erythropoiesis-stimulating agents luspatercept and lenalidomide used to ameliorate a …
Therapy for lower-risk MDS.
Carraway HE, Saygin C. Carraway HE, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):426-433. doi: 10.1182/hematology.2020000127. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275714 Free PMC article.
Interestingly, some patients with lower-risk MDS can present with an isolated thrombocytopenia for which thrombopoietin receptor analogs such as romiplostim and eltrombopag are options (as long as blast counts are low). ...
Interestingly, some patients with lower-risk MDS can present with an isolated thrombocytopenia for which thrombopoietin receptor analogs suc …
Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
Schifferli A, Nimmerjahn F, Kühne T. Schifferli A, et al. Front Immunol. 2019 Jun 4;10:1196. doi: 10.3389/fimmu.2019.01196. eCollection 2019. Front Immunol. 2019. PMID: 31214173 Free PMC article. Review.
This molecular architecture is seen in drugs, such as etanercept, romiplostim, and the recombinant factor VIII (efmoroctocog alfa). A considerable number of Fc fusion proteins and peptibodies are currently in pre-clinical and clinical development. ...In this short r …
This molecular architecture is seen in drugs, such as etanercept, romiplostim, and the recombinant factor VIII (efmoroctocog a …
Peptibodies: An elegant solution for a long-standing problem.
Cavaco M, Castanho MARB, Neves V. Cavaco M, et al. Biopolymers. 2017 Dec 21. doi: 10.1002/bip.23095. Online ahead of print. Biopolymers. 2017. PMID: 29266205 Review.
Also, the peptides therapeutic activity is boosted by the number of peptides in the fusion protein (at least two peptides) and to some peptides' alterations. Peptibodies are mainly obtained through recombinant DNA technology. However, to improve peptide properties, "unnatu …
Also, the peptides therapeutic activity is boosted by the number of peptides in the fusion protein (at least two peptides) and to some pepti …
Prolonged maintenance of hematopoietic stem cells that escape from thrombopoietin deprivation.
Nakamura-Ishizu A, Chin DWL, Matsumura T, Tan DQ, Mochizuki-Kashio M, Jianwen D, Suda T. Nakamura-Ishizu A, et al. Blood. 2021 May 13;137(19):2609-2620. doi: 10.1182/blood.2020005517. Blood. 2021. PMID: 33657206 Free PMC article.
Moreover, Thpo-/- HSCs acquired quiescence with extended administration of a Thpo receptor agonist, romiplostim, and were prone to subsequent stem cell exhaustion during competitive bone marrow transplantation. ...
Moreover, Thpo-/- HSCs acquired quiescence with extended administration of a Thpo receptor agonist, romiplostim, and were prone to su …
38 results